Smithsonian’s imbalanced stem cell coverage: Will it help dodgy clinics lure desperate patients?
‘Fake breakthrough, fake news:’ One physician-researcher’s takeaway on news coverage of MS drug Ocrevus
What journalists and consumers should know about the tug-of-war between biologics and generic ‘biosimilars’
Grail’s search for a universal cancer screen: noble quest or fool’s errand?
Hypewatch: Journalists need to pour some cold water into that “Grail”
Fred Hutch president predicts cancer cure in 10 years; critics have heard it all before
Money angle is missing from Post’s coverage of a new ALS drug
Some journalists fire another “silver bullet” at Alzheimer’s amyloid target
Sponsored journalist training on “precision medicine”: Zeroing in on a conflict of interest
Why we look for independent perspectives in health/medicine/science news stories